1. HBW Insight
  2. >>Wellness
  4. >>Earnings

Reaching 'Transformation' In Turnaround Phase 1, Perrigo Looks To Build On Its Accomplishments

 
• By Malcolm Spicer

Day after releasing Q4 and full-year results, Perrigo announced launch of next chapter in its “3/5/7” makeover strategy. It reached annual growth of 3% for top line revenues in phase 1, aims for 5% operating income and 7% earnings per share growth in phase 2.

Perrigo provides data on separate periods to show a return to net sales growth with adjusted operating income stabilized as it invested to modernize, partially by restoring its historical growth formula • Source: Perrigo

Perrigo Company PLC is turning the page on its makeover strategy, moving from transforming its portfolio and operations to optimizing its businesses while accelerating growth.

As the consumer health products private label leader touts its path ahead, shareholders likely are noting it ended each of the past two years with the same full-year net loss...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Dermapharm Seeks To Put Stop To Spanish Slide

 
• By Tom Gallen

Dermapharm shakes up management of Arkopharma subsidiary in Spain with turnaround plan not showing results.

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By Tom Gallen

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By Tom Gallen

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.